OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Gibson on Advancements in Biomarker Identification in Gastric/GEJ Adenocarcinoma

May 15th 2023

Michael K. Gibson MD, PhD, discusses advancements in the identification of key biomarkers for patients with gastric or gastroesophageal junction adenocarcinoma, and the subsequent development of biomarker-driven therapeutics in this disease space.

Dr Galsky on the Importance of Improved Disease Classification Within Non–Clear Cell RCC

May 15th 2023

Matthew Galsky, MD, discusses the importance of developing specific disease classifications within non–clear cell renal cell carcinomas.

Dr Reuss on the Investigation of LP-300 in Lung Adenocarcinoma

May 15th 2023

Joshua Reuss, MD, discusses the background of LP-300 and the rationale for evaluating the agent in the phase 2 HARMONIC trial in a never-smoker population of patients with advanced lung adenocarcinoma.

Dr Habermann on the Withdrawal of U.S. Indications for Ibrutinib in MCL and MZL

May 12th 2023

Thomas M. Habermann, MD, discusses the withdrawal of United States indications for ibrutinib in patients with mantle cell lymphoma who have previously received at least 1 therapy and in those with marginal zone lymphoma who require systemic treatment and have received at least 1 prior anti–CD20-based therapy.

Dr Ryan on the Role of Adjuvant Therapy in RCC

May 12th 2023

Christopher W. Ryan, MD, discusses the role of adjuvant therapy for patients with renal cell carcinoma.

Dr Goff on Key Takeaways from the SWOG 1815 Trial in Biliary Tract Cancers

May 12th 2023

Laura Goff, MD, discusses the key takeaways from results of the phase 3 SWOG 1815 trial in newly diagnosed patients with advanced biliary tract cancers.

Dr Zonder on the Management of Bispecific Antibody–Associated Toxicities in Multiple Myeloma

May 12th 2023

Jeffery Zonder, MD, discusses the management of toxicities associated with bispecific antibodies in patients with multiple myeloma.

Dr Khalil on Benefits Derived From the POSEIDON Regimen in Metastatic NSCLC

May 12th 2023

Maya Khalil, MD, discusses the use of first-line durvalumab plus tremelimumab in patients with non–small cell lung cancer enrolled in the phase 3 POSEIDON trial, and sheds light on histologies and mutations that are associated with increased benefit with this regimen.

Dr Gibson on Current and Emerging Biomarkers in Gastric/GEJ Adenocarcinoma

May 11th 2023

Michael K. Gibson MD, PhD, discusses current and emerging biomarkers in the treatment of patients with gastric or gastroesophageal junction adenocarcinoma.

Dr Mascarenhas on the Background of the MANIFEST-2 Trial in Myelofibrosis

May 11th 2023

John Mascarenhas, MD, discusses the background of the phase 3 MANIFEST-2 trial investigating the combination of pelabresib and ruxolitinib vs ruxolitinib plus placebo in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.

Dr Tsao on First-line Treatment Approaches in Clear Cell RCC

May 11th 2023

Che-Kai Tsao, MD, discusses first-line treatment approaches for patients with clear cell renal cell carcinoma.

Dr Anderson on Novel and Emerging Therapeutics in HR+ Breast Cancer

May 11th 2023

Karen S. Anderson, MD, PhD, discusses novel and emerging therapies, as well as potential future targets, for the treatment of patients with hormone receptor–positive breast cancer.

Dr Das on the Limited Landscape of Second-line Treatment Options in ES-SCLC

May 11th 2023

Devika Das, MD, MSHQS, discusses the activity and tolerability of lurbinectedin and topotecan as second-line regimens in extensive-stage small cell lung cancer.

Dr Paz-Ares on the Challenges of NGS in NSCLC

May 10th 2023

Luis G. Paz-Ares, MD, PhD, discusses the importance of next-generation sequencing and highlights current challenges with NGS for patients with non–small cell lung cancer.

Dr Shore on the Rationale for the EMBARK Trial in Nonmetastatic Prostate Cancer

May 10th 2023

Neal Shore, MD, FACS, discusses the rationale for the phase 3 EMBARK trial investigating enzalutamide plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

Dr Mohan on AEs Associated With CAR T-cell Therapy in R/R Myeloma

May 10th 2023

Meera Mohan, MD, MS, FACP, discusses adverse effects associated with CAR T-cell therapy in relapsed/refractory multiple myeloma.

Dr Jain on Baseline Differences Across Different Donor Types in Myelofibrosis

May 10th 2023

Tania Jain, MBBS, discusses notable differences in baseline characteristics and donor sequencing, according to a retrospective study of patient outcomes following blood or marrow transplant in 4 common donor types of myelofibrosis.

Dr Desai on Toxicities Associated with T-DXd in HER2+ Breast Cancer

May 10th 2023

Neelam Desai, MD, discusses the toxicity profile of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Dr Hecht on the Investigation of A2B530 in Germline HLA-A*02 Heterozygous Solid Tumors

May 9th 2023

J. Randolph Hecht, MD, discusses the investigation of A2B530 in germline HLA-A*02 heterozygous solid tumors.

Dr Anderson on the Evolution of ADCs in Metastatic Breast Cancer

May 9th 2023

Karen S. Anderson, MD, PhD, discusses the evolution of antibody-drug conjugates in the treatment of different subgroups of patients with metastatic breast cancer.